Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

被引：0
|
作者：
H-M Lin
L Castillo
K L Mahon
K Chiam
B Y Lee
Q Nguyen
M J Boyer
M R Stockler
N Pavlakis
G Marx
G Mallesara
H Gurney
S J Clark
A Swarbrick
R J Daly
L G Horvath
机构：
[1] The Kinghorn Cancer Centre/Garvan Institute of Medical Research,Cancer Research Division
[2] Sydney Medical School,Department of Medical Oncology
[3] University of Sydney,undefined
[4] Pharmacogenomic Research for Individualised Medicine (PRIMe) consortium,undefined
[5] Chris O’Brien Lifehouse,undefined
[6] Royal Prince Alfred Hospital,undefined
[7] Medical Oncology,undefined
[8] Concord Repatriation General Hospital,undefined
[9] Concord,undefined
[10] Medical Oncology,undefined
[11] Royal North Shore Hospital,undefined
[12] Northern Haematology and Oncology Group,undefined
[13] Sydney Adventist Hospital,undefined
[14] Calvary Mater Newcastle Hospital,undefined
[15] Westmead Hospital,undefined
[16] St Vincent’s Clinical School,undefined
[17] Faculty of Medicine,undefined
[18] UNSW Australia,undefined
[19] Signalling Network Laboratory,undefined
[20] School of Biomedical Sciences,undefined
[21] Monash University,undefined
来源：
British Journal of Cancer | 2014年 / 110卷
关键词：
circulating microRNAs; chemotherapy; metastatic prostate cancer; biomarkers; docetaxel;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2462 / 2471
页数：9
相关论文
共 50 条
  • [1] Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
    Lin, H-M
    Castillo, L.
    Mahon, K. L.
    Chiam, K.
    Lee, B. Y.
    Nguyen, Q.
    Boyer, M. J.
    Stockler, M. R.
    Pavlakis, N.
    Marx, G.
    Mallesara, G.
    Gurney, H.
    Clark, S. J.
    Swarbrick, A.
    Daly, R. J.
    Horvath, L. G.
    BRITISH JOURNAL OF CANCER, 2014, 110 (10) : 2462 - 2471
  • [2] CIRCULATING MICRORNAS ASSOCIATED WITH DOCETAXEL-RESISTANT CASTRATION-RESISTANT PROSTATE CANCER
    Mahon, K. L.
    Chiam, K.
    Lee, B. Y.
    Nguyen, Q.
    Boyer, M. J.
    Stockler, M.
    Pavlakis, N.
    Marx, G.
    Mallesara, G.
    Gurney, H.
    Clark, S.
    Swarbrick, A.
    Daly, R.
    Horvath, Lisa
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 26 - 27
  • [3] Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer
    Horvath, Lisa
    Lin, Hui-Ming
    Castillo, Lesley
    Mahon, Kate Lynette
    Chiam, Karen
    Lee, Brian Yong
    Quoc Nguyen
    Qu, Wenjia
    Boyer, Michael J.
    Stockler, Martin R.
    Pavlakis, Nick
    Marx, Gavin M.
    Gowda, Girish Mallesara Hiriyanna
    Gurney, Howard
    Clark, Susan J.
    Swarbrick, Alex
    Daly, Roger J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [4] Validation of circulating microRNA biomarkers of docetaxel outcome in castration-resistant prostate cancer
    Lin, H. M.
    Mahon, K. L.
    Spielman, C.
    Gurney, H.
    Mallesara, G.
    Stockler, M.
    Briscoe, K.
    Marx, G.
    Horvath, L. G.
    BJU INTERNATIONAL, 2016, 118 : 22 - 22
  • [5] Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
    Kume, Haruki
    Kawai, Taketo
    Nagata, Masayoshi
    Azuma, Takeshi
    Miyazaki, Hideyo
    Suzuki, Motofumi
    Fujimura, Tetsuya
    Nakagawa, Tohru
    Fukuhara, Hiroshi
    Homma, Yukio
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 303 - 307
  • [6] Circulating micrornas, potentially associated with progression during therapy in castration-resistant prostate cancer
    Kobelyatskaya, A.
    Pudova, E.
    Nyushko, K.
    Krasnov, G.
    Fedorova, M.
    Snezhkina, A.
    Razmakhaev, G.
    Dolotkazin, D.
    Kiseleva, M.
    Kaprin, A.
    Alekseev, B.
    Kudryavtseva, A.
    VIRCHOWS ARCHIV, 2020, 477 : S144 - S145
  • [7] Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
    Brian Schurko
    William K Oh
    Nature Clinical Practice Oncology, 2008, 5 : 506 - 507
  • [8] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
    Schurko, Brian
    Oh, William K.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (09): : 506 - 507
  • [10] Is chemical/surgical castration necessary during docetaxel chemotherapy for castration-resistant prostate cancer?
    Watanabe, Masahito
    Kanao, Kent
    Muramatsu, Hiroyuki
    Morinaga, Shingo
    Kajikawa, Keishi
    Kobayashi, Ikuo
    Nishikawa, Genya
    Kato, Yoshiharu
    Nakamura, Kogenta
    Sumitomo, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345